Skip to content

Colorado’s first licensed cannabis R&D firm to study marijuana’s effect on Alzheimer’s disease

March 6, 2020 / Arfinn Med MD /

Colorado’s first licensed cannabis R&D firm to study marijuana’s effect on Alzheimer’s disease

A Denver-based company hopes to be the state’s first to study the effects of marijuana on Alzheimer’s disease, thanks to a newly available research and development license in the city.

MedPharm Holdings plans to apply for a Denver marijuana R&D license to test delta-9 tetrahydrocannabinol (THC), cannabidiol (CBD) and other cannabinoids’ effects on Alzheimer’s and dementia patients.

According to the Alzheimer’s Association, 5.8 million Americans have the disease, a degenerative brain disorder that affects a person’s memory and thinking skills. While there are drugs that help ease symptoms, they do not change the course of the disease.

Albert Gutierrez, CEO of MedPharm, sees Alzheimer’s as “one of the biggest things that’s plaguing our country now and in the future.” That’s why he’s excited about cannabis’ potential to treat it.

Read Full Article Here

Stories you may be interested in

You Can Get A Master’s In Medical Cannabis In Maryland

Summer Kriegshauser is one of 150 students in the inaugural class of the University of Maryland, Baltimore’s Master of Science in Medical Cannabis Science and Therapeutics, the first graduate program of its type in the country. This will be Kriegshauser’s second master’s degree and she hopes it will offer her a chance to change careers. “I…
Read More →

States with medical marijuana laws saw 20 percent drop in some opioid prescriptions

States with active medical marijuana laws saw certain opioid prescription rates drop nearly 20 percent compared to states without medical marijuana programs, according to a first-of-its-kind study out of Columbia University’s Irving Medical Center. Authors said the findings underscore the importance of providing patients with pain management alternatives, such as cannabis, in efforts to reduce…
Read More →

COVID-19 and medical cannabis patients: What you need to know

In the midst of the COVID-19 maelstrom, the recent shuttering of nonessential stores has created concern around access to cannabis, particularly for medicinal cannabis consumers. Those who depend on cannabis for therapeutic purposes will be relieved to learn that across the US, medical cannabis dispensaries have been deemed essential services, comparable to pharmacies. As of March…
Read More →

Unstructured EHR data more useful for predictive analytics, study shows

A new report in the Journal of the American Medical Informatics Association has shown that real-world data contained in unstructured narratives has big predictive value when it comes to clinical research. WHY IT MATTERSWhile structured clinical notes in the electronic health record have obvious value, the research in JAMIA suggests that real-world data captured in unstructured notes…
Read More →

New Feature Updates

It’s a new feature alert! At Arfinn Med we always work to make sure we are the industry leading software platform and EMR for medical cannabis providers and clinics. Keeping with that sentiment, we’ve recently updated two features that have been very popular with Arfinn Med users.  Those are the customizable consent and confirmation page…
Read More →

IBD and Cannabinoid Medicine

With an estimated 3.1 million adults diagnosed with Irritable Bowel Disease (IBD) in the United States, it’s natural that many people are asking about the possible benefits of cannabis for the symptoms associated with IBD. In fact, the University of Michigan Health Department received so many questions regarding this issue, that they released a Q&A…
Read More →

Leave a Comment

You must be logged in to post a comment.